ArticleDrug design, development and therapy2025
Analysis of Blood Components and Target Prediction for the Combined Use of
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A mechanistic study on the enhanced antihypertensive effects of aFrontiers in cell and developmental biology · 2026Article
- Synergistic Effects of Compound Dendrobium Candidum and Antihypertensive Medications on Refractory Hypertension in Spontaneously Hypertensive Rats.Cardiology research and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the Study: To investigate the primary monomer components and the associated mechanisms of action of DOC in exerting antihypertensive effects with Western medicine. Materials and Methods: In this study, UPLC-Q-TOF/MS technology was used to analyze the blood components of DOC and its interaction with Western medicine. The antihypertensive effects of serum monomer components were also evaluated. Blood pressure measurements for experimental animals were recorded before administration, at three hours and twenty-four hours after the first administration, as well as the same time of the last administration of the treatment cycle. Meanwhile, the antihypertensive mechanism was explored through the integration of network pharmacology and molecular docking technology. Results: Blood component analyses revealed the identification of five compounds in the serum: Kaempferide, Rutin, Syringaldehyde, Paeoniflorin, and Hyperoside. In terms of serum drug concentrations, Irbesartan and Amlodipine concentrations were multiplied by 1.36 and 0.56, respectively, following the combination therapy of Chinese and Western medicine compared with the Western medicine alone group. The concentrations of Paeoniflorin, Kaempferin, and Syringaldehyde in the combination group were significantly higher than those observed in the DOC group. The results from pharmacodynamic experiments indicated that the antihypertensive effect achieved through the combined application of Chinese and Western medicine on SHRs was superior to that resulting from the dual administration of two types of Western medicines alone. Conclusion: The combination of DOC with two Western medications has been shown to significantly enhance antihypertensive effects in SHRs. Furthermore, five major monomers present in the serum of experimental rats post-treatment exhibit notable antihypertensive properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.